Plain English Summary
Background and study aims
Treatment with 90YIbritumomab/tiuxetan (90Y-IT) in CD20+ for non Hodgkin lymphoma (NHL) patients is safe and effective. We have reviewed our hospital database to analyse the outcomes of CD20+ NHL patients over 65 years old treated with 90Y-IT
Who can participate?
Patients diagnosed with CD20+ indolent NHL.
What does the study involve?
To analyze the results of therapy with 90Y-Ibritumomab/tiuxetan in clinical practice prescription.
What are the possible benefits and risks of participating?
90Y-IT has demonstrated high efficacy and safety in the therapy of CD20+ indolent NHL patients. We want to analyse these aspects in patients treated over 65 years old and to evaluate safety, survival and comorbidities in the long term.
Where is the study run from?
The Miguel Servet University Hospital, Zaragoza (Spain).
When is the study starting and how long is it expected to run for?
The study started in September 2005 when the first patient received therapy with 90Y-IT in the
Miguel Servet University Hospital.
Who is funding the study?
The Foundation for the Study of Hematology in Aragon (FEHHA)
Who is the main contact?
Dr Pilar Giraldo
fehha@fehha.org
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
RIT-002
Study information
Scientific title
Radioimmunotherapy with 90Y Ibritumumab Tiuxetan in B-cell CD20+ indolent non-Hodgkin Lymphoma: A retrospective study
Acronym
RIT
Study hypothesis
Radioimmunotherapy (RIT) emerged as an option after Mo-Ab success, combining the selectivity of the anti CD-20 immunotherapy with an attached radioisotope, making possible the delivery of radiation exactly within the tumor burden. The previous phase III randomized study that compared 90Y-IT with Rituximab immunotherapy in relapsed or refractory low-grade follicular or transformed CD20+ NHL showed significant ORR for the 90Y-IT group vs the Rituximab group. In addition the results of the phase III randomized study of 90Y-IT as front-line consolidation, the First-line Indolent Trial (FIT) published in 2008, showed that 90Y-IT consolidation significantly prolonged median Progression Free Survival (PFS) after a median of 3.5 years of observation, and converted 77% of Partial Response (PR) after induction into CR, resulting in a CR rate of 87% with low associated toxicity.
We incorporated RIT with 90Y Ibritumumab Tiuxetan in B-cell CD20+ indolent non-Hodgkin Lymphoma since 2005 according an a clinical protocol conducted by a multidisciplinary team formed by clinical hematologists, nuclear medicine physicians, radiopharmacy physicians and nurses in the Miguel Servet University Hospital at Saragossa, Spain. In 2007 the therapeutic inclusion was extended as consolidation after first-line chemotherapy in patients with complete or partial response confirmed by PET/CT. All patients had been treated and follow-up with the same criteria and now we want to analyze retrospectively the results after long term follow-up.
Ethics approval
Ethics Committee Comite de estudios de investigación clínica de Aragón (CEICA),
Study design
Interventional non-randomised retrospective study
Primary study design
Interventional
Secondary study design
Non randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
B-cell CD20+ indolent non-Hodgkin Lymphoma
Intervention
A retrospective study based in a clinical protocol conducted by a multidisciplinary team comprising clinical hematologists, nuclear medicine physicians, radiopharmacists, and nurses at MSUH
Therapy with 90-YIbritumomab/tiuxetan in relapsed and refractory indolent B-cell NHL and in consolidation after first-line immuno- or chemoimmunotherapy.
The study is open in one arm and all patients received an intravenously infusion of Rituximab on day 1 at dose of 250 mg/m2 and a second dose of Rituximab 250 mg/m2 on day 7 followed by weight-based dose of 90Y-IT administered as slow intravenous push over 10 minutes within the next 4 hours of Rituximab infusion.
Intervention type
Drug
Phase
Phase IV
Drug names
90Y Ibritumumab Tiuxetan
Primary outcome measures
Response assessment was made 12 weeks after treatment
PET/CT scan was performed in all cases and response criteria used were the same as the International Working Group (IWG). and classified as Complete Response (CR), Partial Response (PR) and no response (NR).
Secondary outcome measures
1. Time to Progression (TTP)
2. Overall Response (OR) and OS in all patients.
3. We also registered side effects, with special emphasis in myelotoxicity and emerging second neoplasms.
TTP and OS were calculated from the date of 90Y-IT therapy until disease progression or death. All eligible patients were accepted by the clinical committee and included into the analysis.
Overall trial start date
01/09/2005
Overall trial end date
29/02/2012
Reason abandoned
Eligibility
Participant inclusion criteria
1. Adults patients with an excisional biopsy-confirmed diagnosis of CD20+ F-NHL grade 1, 2, or 3a according to the revised WHO classification system
2. ECOG performance status ≤ 2
3. Absolute neutrophil count (ANC) ≥ 1,500/μL
4. Absolute platelet count (APC) ≥ 100,000/μL
5. Bone marrow total lymphocytes ≤ 25% by morphological counting
6. Serum bilirubin ≤ 2.0mg/dL and serum creatinine ≤ 2.0mg/dL
7. All patients were requested to sign an informed consent form
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
50 or more
Participant exclusion criteria
1. Presence of any other malignancy or history of prior malignancy within 5 years of study entry. This does not apply to-non melanoma skin tumors and in situ cervical cancer.
2. Prior radioimmunotherapy
3. Presence of primary central nervous system (CNS) lymphoma at first diagnosis
4. Known seropositivity for hepatitis C virus (HCV) or hepatitis B surface antigen (HbsAg).
5. Known history of HIV infection
6. Abnormal liver function: total bilirubin > 2 × ULN unless secondary to Gilbert disease.
7. Abnormal renal function: serum creatinine > 2.0 × ULN
8. Ongoing toxic effects of chemotherapy > grade 2 and expected to interfere with Zevalin® treatment.
Recruitment start date
01/09/2005
Recruitment end date
29/02/2012
Locations
Countries of recruitment
Spain
Trial participating centre
Haematology Department
Zaragoza
50009
Spain
Sponsor information
Organisation
Foundation for the Study of hematology in Aragon [Fundación para el Estudio de la Hematologia y Hemoterapia en Aragón](FEHHA)
Sponsor details
Lacarra de Miguel
35 2ºizda
Zaragoza
50008
Spain
Sponsor type
Not defined
Website
Funders
Funder type
Research organisation
Funder name
Foundation for the Study of hematology in Aragon [Fundación para el Estudio de la Hematologia y Hemoterapia en Aragón](FEHHA) (Spain)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24985089